Cited by 68Extracellular vesicles in diseaseRespiratory Support and MechanismsMesenchymal stem cell research

MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model

Open access
Kaspi, Haggai, Semo, Jonathan, Abramov, Nathalie, Dekel, Chen, Lindborg, Stacy, Kern, Ralph, Lebovits, Chaim, Aricha, Revital·2021·Stem Cell Research & Therapy

Abstract

Background: One of the most severe complications of the current COVID-19 pandemic is acute respiratory distress syndrome (ARDS). ARDS is caused by increased amounts of pro-inflammatory cytokines, leading to lung damage and loss of lung function. There are currently no effective therapies for combatting ARDS. Mesenchymal stem cells (MSCs) have been suggested as a potential treatment for ARDS due to their significant immunomodulatory properties. MSC small extracellular vesicles (sEVs), including exosomes, modulate the immune response as effectively as MSCs themselves, with the added advantages of increased safety and tissue penetration. Methods: We isolated sEVs from MSCs induced to secrete increased levels of neurotrophic and immunomodulatory factors, termed Exo MSC-NTF, and compared their ability to treat ARDS, in a lung injury LPS mouse model, to sEVs isolated from naïve MSCs (Exo MSC). Measurments of lung histopathological changes and neutrophil infiltration, blood oxygen saturation, and bronchoalveolar lavge fluid (BALF) proinflammatory cytokines and coagulation related factors were performed. Results: We found that Exo MSC-NTF was superior to Exo MSC in reducing LPS-induced ARDS markers, including physiological lung damage such as alveolar wall thickness, fibrin presence, and neutrophil accumulation, as well as increasing oxygenation levels. Furthermore, Exo MSC-NTF reversed the imbalance in the host immune response, seen as decreased IFN-γ, IL-6, TNF-α, and RANTES levels in the bronchoalveolar lavage fluid. Conclusions: These positive preclinical results suggest that Exo MSC-NTF may be suitable as a therapy for COVID-19-induced ARDS and are more effective at combatting ARDS physiological, pathological, and biochemical symptoms than sEVs isolated from non-induced MSCs.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13287-021-02143-w

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kaspi, H., Semo, J., Abramov, N., Dekel, C., Lindborg, S., Kern, R., Lebovits, C., & Aricha, R.
Corresponding author
Aricha, Revital
Venue
Stem Cell Research & Therapy
Published
2021-01-19
Volume
12
Issue
1
Pages
72-72
ISSN
1757-6512 (ISSN-L)
OpenAlex
W3123094951
Cited by
68
References
37
Citations by year
2026: 7 · 2025: 15 · 2024: 12 · 2023: 17 · 2022: 12 · 2021: 5
FWCI
3.61
Type
journal article
Language
en
Open access
Locations
  • Stem Cell Research & Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
Keywords
acute respiratory distress syndrome, mesenchymal stem cell-derived exosomes, small extracellular vesicles, lipopolysaccharide-induced lung injury, COVID-19 pandemic, inflammatory cytokines, neutrophil infiltration, immunomodulation, oxygenation, bronchoalveolar lavage fluid, coagulation factors, interferon-gamma, interleukin-6, TNF-α, RANTES
MeSH terms
Animals, Disease Models, Animal, Female, Humans, Lipopolysaccharides, Respiratory Distress Syndrome, Mesenchymal Stem Cell Transplantation, Mice, Exosomes, Immunomodulation, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review